BioXcel Therapeutics, Inc. — Form 8-K
Filed August 25, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 78/100
What the filing says
BioXcel Therapeutics executed the Fourteenth Amendment to its credit agreement dated August 24, 2026, adding a $1,250,000 Amendment No. 14 Term Loan from existing lenders (primarily Oaktree Capital funds and Qatar Investment Authority affiliate). Total facility increases from $202.3M to $203.6M. Key condition: borrower must execute definitive agreements for a transaction by August 31, 2026 that either pays debt in full or represents an acceptable alternative capital solution. Upfront fee is 20% of the new tranche commitment.
Why this rating
Modest debt increase ($1.25M ≈ 11.4% of $11M market cap) but urgent covenant requiring imminent transaction announcement signals acute distress. Company-scale material event.
See more from August 25, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.